Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer

Cell

Volumn 166, Issue 3, 2016, Pages 755-765

  Zhang, Hui ^a,k   Liu, Tao ^b,k   Zhang, Zhen ^a,k   Payne, Samuel H ^b,k   Zhang, Bai ^a   McDermott, Jason E ^b,k   Zhou, Jian Ying ^a   Petyuk, Vladislav A ^b   Chen, Li ^a   Ray, Debjit ^b   Sun, Shisheng ^a   Yang, Feng ^b   Chen, Lijun ^a   Wang, Jing ^c   Shah, Punit ^a   Cha, Seong Won ^d   Aiyetan, Paul ^a   Woo, Sunghee ^d   Tian, Yuan ^a   Gritsenko, Marina A ^b   Clauss, Therese R ^b   Choi, Caitlin ^a   Monroe, Matthew E ^b   Thomas, Stefani ^a   Nie, Song ^b   Wu, Chaochao ^b   Moore, Ronald J ^b   Yu, Kun Hsing ^e   Tabb, David L ^c,k   Fenyö, David ^f,k   Vineet, V ^g   Wang, Yue ^h,k   Rodriguez, Henry ^i,k   Boja, Emily S ^i,k   Hiltke, Tara ^i,k   Rivers, Robert C ^i,k   Sokoll, Lori ^a   Zhu, Heng ^a,k   Shih, Ie Ming ^a,k   Cope, Leslie ^a,k   Pandey, Akhilesh ^a,k   Zhang, Bing ^c,k   Snyder, Michael P ^e,k   Levine, Douglas A ^j,k   Smith, Richard D ^b,k   Chan, Daniel W ^a,k   Rodland, Karin D ^b,k   Carr, Steven A ^k   Gillette, Michael A ^k   Klauser, Karl R ^k   Kuhn, Eric ^k   Mani, D R ^k   Mertins, Philipp ^k   Ketchum, Karen A ^k   Thangudu, Ratna ^k   Cai, Shuang ^k   Oberti, Mauricio ^k   Paulovich, Amanda G ^k   Whiteaker, Jeffrey R ^k   Edwards, Nathan J ^k   McGarvey, Peter B ^k   Madhavan, Subha ^k   Wang, Pei ^k   Whiteley, Gordon A ^k   Skates, Steven J ^k   White, Forest M ^k   Kinsinger, Christopher R ^k   Mesri, Mehdi ^k   Shaw, Kenna M ^k   Stein, Stephen E ^k   Rudnick, Paul ^k   Zhao, Yingming ^k   Chen, Xian ^k   Ransohoff, David F ^k   Hoofnagle, Andrew N ^k   Liebler, Daniel C ^k   Sanders, Melinda E ^k   Shi, Zhiao ^k   Slebos, Robbert J C ^k   Zimmerman, Lisa J ^k   Davies, Sherri R ^k   Ding, Li ^k   Ellis, Matthew J C ^k   Townsend, R Reid ^k   more..

^a DEPARTMENT OF PATHOLOGY   (United States)

^b PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h Virginia Polytechnic Institute and State University   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^k NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; HISTONE H4; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; DNA; PHOSPHOPROTEIN; PROTEOME; TUMOR PROTEIN;

AMINO ACID METABOLISM; ARTICLE; CANCER GRADING; CANCER STAGING; CHROMOSOMAL INSTABILITY; COPY NUMBER VARIATION; FEMALE; GENE REARRANGEMENT; HIGH GRADE SEROUS OVARY CARCINOMA; HISTONE ACETYLATION; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN ACETYLATION; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEOMICS; RNA SPLICING; SIGNAL TRANSDUCTION; ACETYLATION; DNA REPAIR; GENE DOSAGE; GENETICS; MASS SPECTROMETRY; NEOPLASM; OVARY TUMOR; SURVIVAL ANALYSIS;

ACETYLATION; CHROMOSOMAL INSTABILITY; DNA REPAIR; DNA, NEOPLASM; FEMALE; GENE DOSAGE; HUMANS; MASS SPECTROMETRY; NEOPLASM PROTEINS; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; PHOSPHOPROTEINS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOME; SURVIVAL ANALYSIS;

EID: 84977611330     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2016.05.069     Document Type: Article

References (45)

1. Barrès, V., Ouellet, V., Lafontaine, J., Tonin, P.N., Provencher, D.M., Mes-Masson, A.M., An essential role for Ran GTPase in epithelial ovarian cancer cell survival. Mol. Cancer, 9, 2010, 272.
2. Cai, R.L., Yan-Neale, Y., Cueto, M.A., Xu, H., Cohen, D., HDAC1, a histone deacetylase, forms a complex with Hus1 and Rad9, two G2/M checkpoint Rad proteins. J. Biol. Chem. 275 (2000), 27909–27916.
3. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474 (2011), 609–615.
4. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489 (2012), 519–525.
5. Collins, B.C., Gillet, L.C., Rosenberger, G., Röst, H.L., Vichalkovski, A., Gstaiger, M., Aebersold, R., Quantifying protein interaction dynamics by SWATH mass spectrometry: application to the 14-3-3 system. Nat. Methods 10 (2013), 1246–1253.
6. Cope, L., Wu, R.C., Shih, IeM., Wang, T.L., High level of chromosomal aberration in ovarian cancer genome correlates with poor clinical outcome. Gynecol. Oncol. 128 (2013), 500–505.
7. Creighton, C.J., Hernandez-Herrera, A., Jacobsen, A., Levine, D.A., Mankoo, P., Schultz, N., Du, Y., Zhang, Y., Larsson, E., Sheridan, R., et al., Cancer Genome Atlas Research Network. Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma. PLoS ONE, 7, 2012, e34546.
8. Dizon, D.S., Damstrup, L., Finkler, N.J., Lassen, U., Celano, P., Glasspool, R., Crowley, E., Lichenstein, H.S., Knoblach, P., Penson, R.T., Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer. Int. J. Gynecol. Cancer 22 (2012), 979–986.
9. Fanjul-Fernández, M., Quesada, V., Cabanillas, R., Cadiñanos, J., Fontanil, T., Obaya, A., Ramsay, A.J., Llorente, J.L., Astudillo, A., Cal, S., López-Otín, C., Cell-cell adhesion genes CTNNA2 and CTNNA3 are tumour suppressors frequently mutated in laryngeal carcinomas. Nat. Commun., 4, 2013, 2531.
10. Farmer, H., McCabe, N., Lord, C.J., Tutt, A.N., Johnson, D.A., Richardson, T.B., Santarosa, M., Dillon, K.J., Hickson, I., Knights, C., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005), 917–921.
11. Gadducci, A., Lanfredini, N., Sergiampietri, C., Antiangiogenic agents in gynecological cancer: State of art and perspectives of clinical research. Crit. Rev. Oncol. Hematol. 96 (2015), 113–128.
12. Gong, F., Miller, K.M., Mammalian DNA repair: HATs and HDACs make their mark through histone acetylation. Mutat. Res. 750 (2013), 23–30.
13. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
14. Jovanovic, M., Rooney, M.S., Mertins, P., Przybylski, D., Chevrier, N., Satija, R., Rodriguez, E.H., Fields, A.P., Schwartz, S., Raychowdhury, R., et al. Immunogenetics. Dynamic profiling of the protein life cycle in response to pathogens. Science, 347, 2015, 1259038.
15. Kislinger, T., Cox, B., Kannan, A., Chung, C., Hu, P., Ignatchenko, A., Scott, M.S., Gramolini, A.O., Morris, Q., Hallett, M.T., et al. Global survey of organ and organelle protein expression in mouse: combined proteomic and transcriptomic profiling. Cell 125 (2006), 173–186.
16. Köbel, M., Huntsman, D., Gilks, C.B., Critical molecular abnormalities in high-grade serous carcinoma of the ovary. Expert Rev. Mol. Med., 10, 2008, e22.
17. Komili, S., Silver, P.A., Coupling and coordination in gene expression processes: a systems biology view. Nat. Rev. Genet. 9 (2008), 38–48.
18. Kuo, K.T., Guan, B., Feng, Y., Mao, T.L., Chen, X., Jinawath, N., Wang, Y., Kurman, R.J., Shih, IeM., Wang, T.L., Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res. 69 (2009), 4036–4042.
19. Langfelder, P., Horvath, S., WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics, 9, 2008, 559.
20. Liu, J., Matulonis, U.A., New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advances. Clin. Cancer Res. 20 (2014), 5150–5156.
21. Lu, P., Vogel, C., Wang, R., Yao, X., Marcotte, E.M., Absolute protein expression profiling estimates the relative contributions of transcriptional and translational regulation. Nat. Biotechnol. 25 (2007), 117–124.
22. Mackay, H.J., Hirte, H., Colgan, T., Covens, A., MacAlpine, K., Grenci, P., Wang, L., Mason, J., Pham, P.A., Tsao, M.S., et al. Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. Eur. J. Cancer 46 (2010), 1573–1579.
23. Marguerat, S., Schmidt, A., Codlin, S., Chen, W., Aebersold, R., Bähler, J., Quantitative analysis of fission yeast transcriptomes and proteomes in proliferating and quiescent cells. Cell 151 (2012), 671–683.
24. McEllin, B., Camacho, C.V., Mukherjee, B., Hahm, B., Tomimatsu, N., Bachoo, R.M., Burma, S., PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res. 70 (2010), 5457–5464.
25. Meng, H., Tian, L., Zhou, J., Li, Z., Jiao, X., Li, W.W., Plomann, M., Xu, Z., Lisanti, M.P., Wang, C., Pestell, R.G., PACSIN 2 represses cellular migration through direct association with cyclin D1 but not its alternate splice form cyclin D1b. Cell Cycle 10 (2011), 73–81.
26. Mertins, P., Yang, F., Liu, T., Mani, D.R., Petyuk, V.A., Gillette, M.A., Clauser, K.R., Qiao, J.W., Gritsenko, M.A., Moore, R.J., et al. Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol. Cell. Proteomics 13 (2014), 1690–1704.
27. Mertins, P., Mani, D.R., Ruggles, K.V., Gillette, M.A., Clauser, K.R., Wang, P., Wang, X., Qiao, J.W., Cao, S., Petralia, F., et al., NCI CPTAC. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534 (2016), 55–62.
28. Mielcarek, M., Zielonka, D., Carnemolla, A., Marcinkowski, J.T., Guidez, F., HDAC4 as a potential therapeutic target in neurodegenerative diseases: a summary of recent achievements. Front. Cell. Neurosci., 9, 2015, 42.
29. Modesitt, S.C., Sill, M., Hoffman, J.S., Bender, D.P., Gynecologic Oncology Group. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 109 (2008), 182–186.
30. Pradeep, S., Kim, S.W., Wu, S.Y., Nishimura, M., Chaluvally-Raghavan, P., Miyake, T., Pecot, C.V., Kim, S.J., Choi, H.J., Bischoff, F.Z., et al. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell 26 (2014), 77–91.
31. Ross, P.L., Huang, Y.N., Marchese, J.N., Williamson, B., Parker, K., Hattan, S., Khainovski, N., Pillai, S., Dey, S., Daniels, S., et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 3 (2004), 1154–1169.
32. Ruggles, K.V., Tang, Z., Wang, X., Grover, H., Askenazi, M., Teubl, J., Cao, S., McLellan, M.D., Clauser, K.R., Tabb, D.L., et al. An analysis of the sensitivity of proteogenomic mapping of somatic mutations and novel splicing events in cancer. Mol. Cell. Proteomics 15 (2016), 1060–1071.
33. Tang, J., Cho, N.W., Cui, G., Manion, E.M., Shanbhag, N.M., Botuyan, M.V., Mer, G., Greenberg, R.A., Acetylation limits 53BP1 association with damaged chromatin to promote homologous recombination. Nat. Struct. Mol. Biol. 20 (2013), 317–325.
34. Vang, R., Levine, D.A., Soslow, R.A., Zaloudek, C., Shih, IeM., Kurman, R.J., Molecular alterations of TP53 are a defining feature of ovarian high-grade serous carcinoma: a rereview of cases lacking TP53 mutations in The Cancer Genome Atlas Ovarian Study. Int. J. Gynecol. Pathol. 35 (2016), 48–55.
35. Verhaak, R.G., Tamayo, P., Yang, J.Y., Hubbard, D., Zhang, H., Creighton, C.J., Fereday, S., Lawrence, M., Carter, S.L., Mermel, C.H., et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest. 123 (2013), 517–525.
36. Vogel, C., Marcotte, E.M., Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat. Rev. Genet. 13 (2012), 227–232.
37. Woo, S., Cha, S.W., Na, S., Guest, C., Liu, T., Smith, R.D., Rodland, K.D., Payne, S., Bafna, V., Proteogenomic strategies for identification of aberrant cancer peptides using large-scale next-generation sequencing data. Proteomics 14 (2014), 2719–2730.
38. Woodbine, L., Gennery, A.R., Jeggo, P.A., The clinical impact of deficiency in DNA non-homologous end-joining. DNA Repair (Amst.) 16 (2014), 84–96.
39. Wu, L., Candille, S.I., Choi, Y., Xie, D., Jiang, L., Li-Pook-Than, J., Tang, H., Snyder, M., Variation and genetic control of protein abundance in humans. Nature 499 (2013), 79–82.
40. Yang, L., Duff, M.O., Graveley, B.R., Carmichael, G.G., Chen, L.L., Genomewide characterization of non-polyadenylated RNAs. Genome Biol., 12, 2011, R16.
41. Yang, J.Y., Yoshihara, K., Tanaka, K., Hatae, M., Masuzaki, H., Itamochi, H., Takano, M., Ushijima, K., Tanyi, J.L., Coukos, G., et al., Cancer Genome Atlas (TCGA) Research Network. Predicting time to ovarian carcinoma recurrence using protein markers. J. Clin. Invest. 123 (2013), 3740–3750.
42. Yi, B., Zhang, Y., Zhu, D., Zhang, L., Song, S., He, S., Zhang, B., Li, D., Zhou, J., Overexpression of RhoGDI2 correlates with the progression and prognosis of pancreatic carcinoma. Oncol. Rep. 33 (2015), 1201–1206.
43. Yu, G., Zhang, B., Bova, G.S., Xu, J., Shih, IeM., Wang, Y., BACOM: in silico detection of genomic deletion types and correction of normal cell contamination in copy number data. Bioinformatics 27 (2011), 1473–1480.
44. Zhang, B., Li, H., Riggins, R.B., Zhan, M., Xuan, J., Zhang, Z., Hoffman, E.P., Clarke, R., Wang, Y., Differential dependency network analysis to identify condition-specific topological changes in biological networks. Bioinformatics 25 (2009), 526–532.
45. Zhang, B., Wang, J., Wang, X., Zhu, J., Liu, Q., Shi, Z., Chambers, M.C., Zimmerman, L.J., Shaddox, K.F., Kim, S., et al., NCI CPTAC. Proteogenomic characterization of human colon and rectal cancer. Nature 513 (2014), 382–387.